AMENDMENTS TO THE CLAIMS

1. (Amended) A pharmaceutical composition for treating or preventing an allergic reaction associated with increased IgE levels in a mammal comprising the following compounds:

Genus A,



Genus B, and



Genus C,



wherein X and Y are independently selected from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, hydroxy, halogen, amino, alkylamino, nitro, cyano, CF_3, OCF_3. $CONH_2$, CONHR and $NHCOR_1$;

wherein R is selected from the group consisting of H, CH_3, C_2H_5, C_3H_7, C_4H_9, CH_2Ph, $CH_2C_6H_4$-F(p-), $COCH_3$, $CO_2CH_2CH_3$, aminoalkyl and dialkylaminoalkyl; and

wherein R_1 and R_2 are independently selected from the group consisting of H, aryl, heteroaryl, thiophene, pyridyl, thiazolyl, isoxazolyl, oxazolyl, pyrimidinyl, substituted aryl, substituted heteroaryl, substituted thiophene, substituted pyridyl, substituted thiazolyl, substituted isoxazolyl, substituted oxazolyl, cycloaryl, cycloheteroaryl, quinolinyl, isoquinolinyl, substituted cycloaryl, substituted cycloheteroaryl, substituted quinolinyl, substituted isoqunolinyl, multi-ring cycloaryl, multi-ring cycloheteroaryl, benzyl, heteroaryl-methyl, substituted benzyl, substituted heteroaryl-methyl alkyl, dialkylaminoalkyl, cycloalkyl, cycloalkyl containing 1-3 heteroatoms, substituted cycloalkyl, substitute cycloalkyl containing 1-3 heteroatoms, multi-ring cycloalkyl, multiring cycloalkyl containing 1-3 heteroatoms, fused-ring aliphatic, fused-ring aliphatic containing 1-3 heteroatoms, cyclopropyl, substituted cyclopropyl, cyclobutyl, substituted cyclobutyl, cyclopentyl, pyrrole, piperidine, substituted cyclopentyl, cyclohexyl, substituted cyclohexyl, cycloheptyl, substituted cycloheptyl, bicycloheptyl, substituted pyrrole, substituted piperidine, bicyclooctyl, bicyclononyl, substituted bicycloalkenyl, adamantyl, and substituted adamantyl, heterocyclic ring, and substituted heterocyclic ring;

wherein at least one of R_1 and R_2 are aromatic groups or heteroaromatic groups; and

wherein R_1 and R_2 cannot both be phenyl groups.

2. (Amended) The pharmaceutical composition of Claim 1, wherein the substituents ~~on said substituted aryl, substituted heteroaryl, substituted thiophene, substituted pyridyl, substituted thiazolyl, substituted isoxazolyl, substituted oxazolyl, substituted cycloaryl, substituted cycloheteroaryl, substituted quinolinyl, substituted isoqunolinyl, substituted benzyl, substituted heteroaryl methyl alkyl, substituted cycloalkyl, substitute cycloalkyl containing 1-3 heteroatoms, substituted cyclopropyl, cyclobutyl, substituted cyclobutyl, substituted cyclopentyl, substituted cyclohexyl, cycloheptyl, substituted cycloheptyl, bicycloheptyl, substituted pyrrole, substituted piperidine, bicyclooctyl, bicyclononyl, substituted bicycloalkenyl, adamantyl, and substituted adamantyl are independently~~ is selected from the group consisting of alkyl, aryl, CF_3, CH_3, OCH_3, OH, CN, $CONH_2$, CONHR, ~~CONR1R2~~ $CONR_1R_2$, COOR and COOH.

3. (Original) The pharmaceutical composition of Claim 1, further comprising at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction.

4. (Original) The pharmaceutical composition of Claim 3, wherein said at least one additional ingredient is selected from the group consisting of a short-acting β_2-adrenergic agonist, a long-acting β_2-adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.

---

5. (Amended) The pharmaceutical composition of Claim 1, wherein the compound is selected from the group consisting of:



(110),



(138),



(584),



(639),



(641)



(643),

A2 cont.



(720),



(807),



(894)



(888)



(895)



(899)



(1156)



(1161)



(1239)



(1240)



(1256)


(1257),


(1258),


(1259),


(1300),


(1301),


(1302),


(1303),


(1304),


(1305), and


(1306)

6. (Amended) A method for treating or preventing an allergic reaction in a mammal wherein said reaction is caused by an increase in IgE levels comprising administering an IgE-suppressing amount of at least one compound of ~~Claim 1~~ following formula:

Genus A,



Genus B, and



Genus C,



wherein X and Y are independently selected from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, hydroxy, halogen, amino, alkylamino, nitro, cyano, CF_3, OCF_3, $CONH_2$, CONHR and $NHCOR_1$;

wherein R is selected from the group consisting of H, CH_3, C_2H_5, C_3H_7, C_4H_9, CH_2Ph, $CH_2C_6H_4$-F(p-), $COCH_3$, $CO_2CH_2CH_3$, aminoalkyl and dialkylaminoalkyl; and

wherein R_1 and R_2 are independently selected from the group consisting of H, aryl, heteroaryl, thiophene, pyridyl, thiazolyl, isoxazolyl, oxazolyl, pyrimidinyl, substituted aryl, substituted heteroaryl, substituted thiophene, substituted pyridyl, substituted thiazolyl, substituted isoxazolyl, substituted oxazolyl, cycloaryl, cycloheteroaryl, quinolinyl, isoquinolinyl, substituted cycloaryl, substituted cycloheteroaryl, substituted quinolinyl, substituted isoqunolinyl, multi-ring cycloaryl, multi-ring cycloheteroaryl, benzyl, heteroaryl-methyl, substituted benzyl, substituted heteroaryl-methyl alkyl, dialkylaminoalkyl, cycloalkyl, cycloalkyl containing 1-3 heteroatoms, substituted cycloalkyl, substitute cycloalkyl containing 1-3 heteroatoms, multi-ring cycloalkyl, multiring cycloalkyl containing 1-3 heteroatoms, fused-ring aliphatic, fused-ring aliphatic containing 1-3 heteroatoms, cyclopropyl, substituted cyclopropyl, cyclobutyl, substituted cyclobutyl, cyclopentyl, pyrrole, piperidine, substituted cyclopentyl, cyclohexyl, substituted cyclohexyl, cycloheptyl, substituted cycloheptyl, bicycloheptyl, substituted pyrrole, substituted piperidine, bicyclooctyl, bicyclononyl, substituted bicycloalkenyl, adamantyl, and substituted adamantyl, heterocyclic ring, and substituted heterocyclic ring;

wherein at least one of R_1 and R_2 are aromatic groups or heteroaromatic groups.

---

7. (Original) The method of Claim 6, further comprising administering in conjunction with at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction.

8. (Original) The method of Claim 7, wherein said additional ingredient is selected from the group consisting of a short-acting β_2-adrenergic agonist, a long-acting β_2-adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.

9. (Amended) The method of Claim 6, wherein the compound is selected from the group consisting of:

A3


(110)


(138)


(342)


(556)


(584)


(639)

A3 cont.



(641)



(643),

A3 cont.



(720),



(807),



(894)



(888)



(895)



(899)

A3 com.



(1156)



(1161)



(1239)



(1240)



(1256)



(1257),



(1258),



(1259),



(1300),



(1301),



(1302),



(1303),



(1304),



(1305), and



(1306).

10. (Amended) A method for treating or preventing asthma in a mammal comprising administering an IgE-suppressing amount of at least one compound of ~~Claim 1~~ following formula:

Genus A,



Genus B, and





Genus C,

wherein X and Y are independently selected from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, hydroxy, halogen, amino, alkylamino, nitro, cyano, CF_3, OCF_3, $CONH_2$, CONHR and $NHCOR_1$;

wherein R is selected from the group consisting of H, CH_3, C_2H_5, C_3H_7, C_4H_9, CH_2Ph, $CH_2C_6H_4$-F(p-), $COCH_3$, $CO_2CH_2CH_3$, aminoalkyl and dialkylaminoalkyl; and

wherein R_1 and R_2 are independently selected from the group consisting of H, aryl, heteroaryl, thiophene, pyridyl, thiazolyl, isoxazolyl, oxazolyl, pyrimidinyl, substituted

aryl, substituted heteroaryl, substituted thiophene, substituted pyridyl, substituted thiazolyl, substituted isoxazolyl, substituted oxazolyl, cycloaryl, cycloheteroaryl, quinolinyl, isoquinolinyl, substituted cycloaryl, substituted cycloheteroaryl, substituted quinolinyl, substituted isoqunolinyl, multi-ring cycloaryl, multi-ring cycloheteroaryl, benzyl, heteroaryl-methyl, substituted benzyl, substituted heteroaryl-methyl alkyl, dialkylaminoalkyl, cycloalkyl, cycloalkyl containing 1-3 heteroatoms, substituted cycloalkyl, substitute cycloalkyl containing 1-3 heteroatoms, multi-ring cycloalkyl, multiring cycloalkyl containing 1-3 heteroatoms, fused-ring aliphatic, fused-ring aliphatic containing 1-3 heteroatoms, cyclopropyl, substituted cyclopropyl, cyclobutyl, substituted cyclobutyl, cyclopentyl, pyrrole, piperidine, substituted cyclopentyl, cyclohexyl, substituted cyclohexyl, cycloheptyl, substituted cycloheptyl, bicycloheptyl, substituted pyrrole, substituted piperidine, bicyclooctyl, bicyclononyl, substituted bicycloalkenyl, adamantyl, and substituted adamantyl, heterocyclic ring, and substituted heterocyclic ring;

wherein at least one of R_1 and R_2 are aromatic groups or heteroaromatic groups.

A3 Cont.

11. (Original) The method of Claim 10 further comprising administering in conjunction with at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction.

12. (Original) The method of Claim 11, wherein said additional ingredient is selected from the group consisting of a short-acting β_2-adrenergic agonist, a long-acting β_2-adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.

13. (Original) The method of Claim 10, wherein the compound is selected from the group consisting of:



(110)



(138)



(342)



(556)



(584)



(639)



(641)



(643),



(720),



(807),



(894)



(888)



(895)



(899)



(1156)



(1161)



(1239)



(1240)



(1256)


(1257),


(1258),


(1259),


(1300),


(1301),


(1302),


(1303),


(1304),


(1305), and


(1306).

Please add the following new claims:

14. (New) The pharmaceutical composition of Claim 1, wherein R_1 or R_2 is aliphatic.

15. (New) The pharmaceutical composition of Claim 1, wherein the compound is selected from the group consisting of


(1239),


(1240),


(1256),


(1258)

A4 Cont.

16. (New) The pharmaceutical composition of Claim 1, wherein the compound is


(1256)